RT Journal Article
SR Electronic
T1 Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept.
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 740
OP 743
VO 32
IS 4
A1 Adam Mor
A1 Clifton Bingham, 3rd
A1 Laura Barisoni
A1 Eileen Lydon
A1 H Michael Belmont
YR 2005
UL http://www.jrheum.org/content/32/4/740.abstract
AB Tumor necrosis factor-alpha (TNF-alpha) is a proinflammatory cytokine. Agents that neutralize TNF-alpha are effective in the treatment of disorders such as rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), spondyloarthropathies, and inflammatory bowel disease. TNF-alpha antagonist therapy has been associated with the development of antinuclear antibodies (ANA) and double-stranded DNA (dsDNA) antibodies, as well as the infrequent development of systemic lupus erythematosus (SLE)-like disease. We describe the first case of biopsy-confirmed proliferative lupus nephritis and leukocytoclastic vasculitis in a patient treated with etanercept for JRA.